GlassScriptPhysician profile
Nora J Lin
NPI 1417950528
$4,533.09
in general payments reported to CMS, 2019-2025
25 companies · $873 in 2025
The $873 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $676 · 2021: $619 · 2022: $504 · 2023: $398 · 2024: $657 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850 · Consulting Fee: $68.85 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.13 |
| Consulting Fee | $68.85 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $994.55 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $633.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $533.20 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Kaleo, INC. | $369.01 | 2019-2024 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $319.96 | 2019-2025 | Dupixent |
| Csl Behring | $252.04 | 2019-2025 | Hizentra, Andembry |
| Aimmune Therapeutics, INC. | $193.72 | 2021-2022 | |
| Genentech USA, INC. | $157.94 | 2019-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.79 | 2020-2021 | |
| Optinose US, INC. | $146.06 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.49 | 2020-2025 | Cuvitru |
| Pfizer INC. | $125.17 | 2019-2024 | |
| Amgen INC. | $96.50 | 2023-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $80.69 | 2020-2021 | |
| Covis Pharma Gmbh | $75.54 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $68.85 | 2025 | |
| Leo Pharma INC. | $46.19 | 2022 | |
| Grifols USA, LLC | $40.89 | 2024-2025 | Xembify |
| Azurity Pharmaceuticals, INC. | $26.66 | 2025 | Alvesco |
| Shire North American Group INC | $23.03 | 2019 | |
| Organon LLC | $20.18 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $16.09 | 2025 | Nemluvio |
| Abbvie INC. | $15.88 | 2022 | |
| Alk-Abello, INC | $14.25 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.